Determination of Crenolanib (CP-868,596) in Human Plasma and Serum by Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry (LC-ESI-MS/MS)

摘要

An LC-ESI-MS/MS method was developed and validated for the rapid and precise quantitation of both plasma and serum concentrations of crenolanib for use in pharmacokinetic studies. Given the need for a highly sensitive analytical method to measure crenolanib concentrations in human plasma, serum, and cerebrospinal fluid samples, we defined the optimal chromatographic and mass spectrometry conditions to enhance our analytical ability to detect crenolanib. Using our method, a S/N ratio of 15.6 can be achieved at the LLOQ of 0.1 ng/mL. Preliminary results of our crenolanib pharmacokinetic studies in patients with high-grade glioma show the utility of this method (Figure 4). Given the relatively small sample requirement and sensitivity of this method, we have further applied it to quantitate crenolanib concentrations in microdialysis samples obtained from orthotopic murine tumor models.